SLC5A2 and diabetic kidney disease: Although standard therapies such as renin–angiotensin system (RAS) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to slow the rate of progression of DKD and reduce the severity of microalbuminuria, the results are still unsatisfactory, especially in patients with normal blood pressure or without microalbuminuria.